Funding news
Amethyst Radiotherapy Group logo

Amethyst Radiotherapy Group Secures $300 Million in Series A Funding to Expand Cancer Treatment Services Across Europe

Recently funded · €300.0M Series aHealthcare

Get the full Amethyst Radiotherapy Group company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Amethyst Radiotherapy Group, a leading provider of non-surgical oncology treatment in Europe, has successfully raised a significant $300,000,000 in funding. The company's mission revolves around helping cancer patients in their fight against the disease, with 15 clinics spread across 6 countries. Amethyst Radiotherapy treats approximately 29,000 patients every year, offering top-quality care through a combination of expert medical professionals, state-of-the-art techniques, and cutting-edge equipment. This latest funding round will further strengthen their ability to provide unparalleled treatment and support to those battling cancer, reinforcing their commitment to delivering exceptional care and outcomes for their patients.

Other recently funded companies

View all

Other recent Series a rounds

Companies that recently closed a Series a round.

#CompanyAmount
1
Scout Space logo

Scout Space

United States

$18.0M
2
Kanvas Biosciences logo

Kanvas Biosciences

United States

$48.0M
3
Bug Bounty Switzerland logo

Bug Bounty Switzerland

$15.2M
4
OnRe logo

OnRe

United Kingdom

$5.0M
5
Dandelion Health logo

Dandelion Health

United States

$14.0M